While issuing quarterly update covering the period from 31 March 2021 to 30 June 2021, Syncona Ltd (SYNC.L) said the Group is pleased with the continued positive clinical progress across its companies over the period with Anaveon dosing the first patient in its clinical programme and becoming the Group's fifth clinical-stage business. Although share prices of the listed holdings have been volatile over the period, Syncona said it remains confident in the companies' fundamentals and recent progress.
For the period, net assets were 1.20 billion pounds, 178.9 pence per share, a NAV return of negative 7.7 percent. Capital base was at 578.0 million pounds on 30 June 2021.
Martin Murphy, CEO, Syncona Investment Management, said: "Whilst we recognise that the share price performance of our listed holdings has brought volatility to our NAV, we remain focused on delivering value over the long-term."
For comments and feedback: editorial@rttnews.com